Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 05/21 06:59:52 pm
176.675 USD   +0.21%
05/18Correction to Buybacks Article on May 10
DJ
05/18AMGEN : Trumpets FDA Nod
AQ
05/18FDA approves Aimovig as first CGRP inhibitor for migraines
AQ
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/15/2018 05/16/2018 05/17/2018 05/18/2018 05/21/2018 Date
172.34(c) 173.8(c) 174.65(c) 176.3(c) 177.11 Last
4 491 682 2 494 165 2 268 360 3 377 156 1 128 942 Volume
-2.06% +0.85% +0.49% +0.94% +0.46% Change
More quotes
Financials (USD)
Sales 2018 22 696 M
EBIT 2018 11 648 M
Net income 2018 8 612 M
Finance 2018 10 236 M
Yield 2018 2,94%
Sales 2019 22 632 M
EBIT 2019 11 632 M
Net income 2019 8 885 M
Finance 2019 11 641 M
Yield 2019 3,15%
P/E ratio 2018 14,42
P/E ratio 2019 13,54
EV / Sales2018 4,64x
EV / Sales2019 4,59x
Capitalization 116 B
More Financials
Company
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics.Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha,... 
Sector
Pharmaceuticals
Calendar
05/22 | 05:00pmShareholder meeting
More about the company
Surperformance© ratings of Amgen
Trading Rating : Investor Rating :
More Ratings
Latest news on AMGEN
05/19AMGEN : FDA Approves Aimovig (erenumab-aooe), A Novel Treatment Developed Specif..
AQ
05/18Correction to Buybacks Article on May 10
DJ
05/18AMGEN : Trumpets FDA Nod
AQ
05/18AMGEN : Today's Research Reports on Trending Tickers: Amgen and Allergan
AC
05/18FDA approves Aimovig as first CGRP inhibitor for migraines
AQ
05/18AMGEN : US approves 1st drug developed to prevent chronic migraines
AQ
05/18AMGEN : FDA Approves Aimovig™ (erenumab-aooe), A Novel Treatment Developed..
PU
05/17AMGEN : Study Results from Amgen Provide New Insights into Nuclear Magnetic Reso..
AQ
05/17FDA approves Pfizers epoetin biosimilar Retacrit
AQ
05/16AMGEN : U.S. Court of Appeals for the D.C. Circuit - Argument Schedule
AQ
More news
Sector news : Pharmaceuticals - NEC
09:01aRoche Presents Positive Results From Hemlibra Trials
DJ
08:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
05/18GLAXOSMITHKLINE : Regulators flag possible birth defect link to GSK's HIV drug
RE
05/18LONDON MARKETS: U.K. Stocks Fall From Record As AstraZeneca, Mining Stocks De..
DJ
05/18NOVARTIS : Greek Parliament to Vote on Prosecutions in Novartis Bribery Case
DJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on AMGEN 
AMGEN - 03/05
The technical configuration is positive
BUY
AMGEN - 2017
Back on key levels based on weekly price data
BUY
More Strategies
Latest Tweets
09:00aHere's how much drugmaker Amgen will charge for a novel migraine treatment in.. 
07:59aLeerink Swann Raises Amgen FY2020 Earnings Estimates to $15.28 EPS (Previousl.. 
07:10a[email protected] gets approval for migraine drug
9
06:00aAmgen gets approval for migraine drug
9
05:05aHere's how much drugmaker Amgen will charge for a novel migraine treatment in..
4
More tweets
Qtime:196
News from SeekingAlpha
05/18J&J bails on Alzheimer's candidate atabecestat on toxicity issues 
05/18YOUR DAILY PHARMA SCOOP : RARE Shows Solid Data, Spectrum Up On Positive Results.. 
05/18Amgen's first mover advantage with Aimovig bodes well - analysts 
05/18Investors bullish on biotechs after Trump drug pricing speech 
05/18How To Retire Today With $1 Million 
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 195 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline CFO, Chief Accounting Officer & Executive VP
John Tsai Chief Medical Officer & SVP-Global Medical
Frank C. Herringer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN1.38%115 567
JOHNSON & JOHNSON-11.36%332 184
PFIZER-1.41%212 424
NOVARTIS-6.55%202 969
ROCHE HOLDING LTD.-8.90%193 622
MERCK AND COMPANY5.10%158 916